Zenas BioPharma Earnings
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.26+1.02 (+3.89%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma earnings summary
In its most recent report on Aug 13, 2026 (Q2 2026), ZBIO posted EPS of $-1.77. Revenue for the quarter was $1.0 million. Across the last 8 reports, ZBIO shares moved an average of 9.4% (in either direction) in the first trading session after results, rising 6 times and falling 2 times.
Summary generated from market data by MetaCap's automated system. Methodology
ZBIO earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 13, 2026 | — | $-1.77 | — | +9.4% |
| May 13, 2026 | — | $-1.46 | — | +3.4% |
| Mar 16, 2026 | — | $-5.17 | — | -18.3% |
| Nov 12, 2025 | — | $-1.22 | — | +2.3% |
| Aug 12, 2025 | — | $-1.25 | — | +1.7% |
| May 15, 2025 | — | $-0.80 | — | +9.2% |
| Mar 11, 2025 | — | $35.25 | — | +1.0% |
| Nov 12, 2024 | — | $-5.02 | — | -29.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.